Upcoming therapeutic advances in diabetic macular edema: An intravitreal dexamethasone drug delivery system

Expert Opinion on Drug Delivery

Volumn 8, Issue 2, 2011, Pages 271-279

  Augustin, Albert J ^a  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

anti VEGF compounds; biodegradable; corticosteroids; dexamethasone; diabetic macular edema; diabetic retinopathy; intraocular drug delivery; intravitreal; macular edema; non biodegradable; pathophysiology of DME; persistent macular edema; sustained drug delivery systems; triamcinolone

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; I VATION; ILUVIEN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VEGF TRAP EYE;

BIODEGRADABILITY; CATARACT; CATARACTOGENESIS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SAFETY; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE;

ABSORBABLE IMPLANTS; ADRENAL CORTEX HORMONES; BLINDNESS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; LASER THERAPY; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79251483192     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.548802     Document Type: Review

References (88)

1. Johnson M. Perspective-Etiology and treatment of macular edema. Am J Ophthalmol 2009;147(1):11
2. Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol 2008;2:919-30
3. Buchholz PM, Buchholz AP, Augustin AJ. Antivascular endothelial growth factor as an approach for macular edema. Dev Ophthalmol 2010;46:111-22
4. Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6):1134-46
5. Hayreh SS. Classification ofcentral retinal vein occlusion. Opthalomology 1983;90:458-74
6. Hayreh SS, Klugmann MR, Beri M, et al. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthamol 1990;228:201-17
7. News Medical Net. FDA approves OZURDEX implant for uveitis treatment. Available from: http://www. news-medical.net/news/20100927/FDA-approves-OZURDEX- implant-for-uveitis-treatment.aspx. [Last accessed 27 September 2010]
8. Kempen JH, O'Colman BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122(4):552-63
9. Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence of future diabetes burden. Diabetes Care 2006;29(9):2114-16
10. Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema in Coscas G. Macular Edema. Dev Ophthalmol 2010;47:73-110
11. GirachA, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract 2007;61:88-97
12. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007;39:1-12
13. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007;8:49-66
14. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular oedema: long-term visual results. Ophthalmology 1991;98:1594-602
15. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthamol 1985 103(12) 1796-806
16. Blumenkranz MS. Treatments for diabetic macular oedema in in Coscas G. Macular Edema. Dev Ophthalmol 2010;47:428-34
17. Lee SS, Hughes P, Ross AD, Robinson MR Biodegradable implants for sustained drug release in the eye. Pharm Res 2010: published online 10 June 2010, doi:10.1007/sI 1095-010-0159-x
18. Ingerman A, Dewey-Mattia D. Emerging treatments for diabetic macular edema. August 2010;8:52-4
19. Massin PG. Ranibizumab indiabetic macular edema. Joint Meet Am Acad Ophthalmol Eur Soc Ophthalmol; Atlanta; 2008
20. Clinical trials.gov. Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema (Restore). Available from: http://clinicaltrials.gov/ct2/show/NCT00687804 [Last accessed 27 September 2010]
21. Clinical trials.gov. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE). Available from: http://clinicaltrials.gov/ct2/show/ NCT00473330 [Last accessed 27 September 2010]
22. Clinical trials.gov. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE). Available from: http://clinicaltrials.gov/ct2/show/ NCT00473382 [Last accesssed 27 September 2010]
23. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
24. Clinical trials.gov. Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema (ATEMD). Available from: http://clinicaltrials.gov/ct2/show/NCT00737971 [Last accessed 27 September 2010]
25. Funk M, Schmidienger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010; PMID: 20711086
26. Yanyali A, Aytug B, Horozoglu F, et al. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144(1):124-6
27. Michaelidis M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of dianetic macular edema (BOLT Study). Ophthalmology 2010;117:1078-86
28. Eyetech, Inc Phase 3 Study evaluates investigational use of Macugen in patients with diabetic macular edema. World Ophthalmology Congress 2010, Berlin
29. Regeneron. VEGF Trap Eye Shows Positive Results in a Phase 2 Study in Patients with Diabetic Macular Edema. Available from: http://files.shareholder. com/downloads/REGN/934782482x0x351302/63dc55eb-d052-42dd-830b-033a00f8ef59/ REGN-News-2010-2-18-General-Release.pdf. [Last accessed 26 September 2010]
30. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109(5):920-7
31. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22(3):200-7
32. Rudinsky CJ, Lavergne V, Katz D. Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can J Ophthalmol 2009;44(5):587-93
33. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115(9):1447-9
34. Joussen AM, Poulaki V, Le ML, et al. A vcentral role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18(12):1450-2
35. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29(5):354-62
36. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56(3):794-814
37. Kragballe K. Topical corticosteroids; mechanisms of action. Acta Derm Venereol Suppl 1989;151:7-10
38. Amsterdam A, Tajima K, Sasson R, et al. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 2002;64:843-50
39. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroids attenuates leukostasiss and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4
40. Itakura H, Akiyama H, Hagimura N, et al. Triamcinolone suppresses interleukin-1beta-mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells. Graefes Arch Clin Exp Ophthalmol 2006;244:226-31
41. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1998;16:398-406
42. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80(2):249-58
43. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007;18(3):235-9
44. Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Rev Med Devices 2009;6(3):277-90
45. Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007;41(3):449-54
46. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5(9):1039-46
47. Barnett PJ. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc, 2009; 2009. p. 3087-90
48. Iluvien, an innovative treatment for diabetic Macular Edema. Alimera Sciences. Available from: www. alimerasciences.com/Products/IluvienOverview/ tabid/82/Default.aspx. [Last accessed 26 September 2010]
49. Schwartz SG, Flynn HW. Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res 2010: published online 22 March 2007, doi:10.1155/2007/52487
50. Campochiaro PA. Data from FAME phase 3 study for Iluvien presented at Angiogenesis 2010. Available from: http://www.news-medical.net/news/20100304/ Data-from-FAME-Phase-3-study-for-Iluvien-presented-at-Angiogenesis-2010.aspx [Last accessed 27 September 2010]
51. Clinical trials.gov. Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema. Available from: www.clinicaltrials.gov/ct2/ show/NCT00502541 [Last accessed 27 September 2010]
52. Kuppermann BD. Steroid implant overview: I-vation TA, Posurdex, Iluvien, and more. Paper presented at the American Academy of Ophthalmology, San Francisco; 2009
53. Clinical Trials. gov. A Study of MK0140 in Diabetic Patients With Macular Edema. Available from: www.clinicaltrials.gov/ct2/show/NCT00692614. [Last accessed 27 September 2010]
54. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29(1):46-51
55. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52(1):80-6
56. Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol 2009;20:511-19
57. Kuppermann BD, Loewenstein A. Drug delivery to the posterior segment of the eye in Coscas G. Macular Edema. Dev Ophthalmol 2010;47:59-72
58. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Dexamethasone DDS Phase II Study Group: randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
59. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-96
60. Kuppermann BD, Chou C, Weinberg DV, et al. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol 2010;128(5):642-3
61. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drugs delivery system for the treatment of macular edema. Retina 2009;29:46-51
62. Safety and Efficacy of a New Treatment in vitrectomized Subjects With Diabetic Macular edema. Clinical Trials.gov. Available from: www. clinicaltrials.gov/ct2/show/NCT00799227 [Last accessed 24 September 2010]
63. Yanyali A, Nohutcu AF, Horozoglu F, et al. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthamol 2005;139(5):795-801
64. Schindler RH, Chandler D, Thresher R, Machemer R The clearance of intravitreal triamcinolone acetonide. Am J Ophthamol 1982;93(4):415-17
65. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25(5):556-60
66. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110(4):681-86
67. Clinical Trials.gov. A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema. Clinical. Available from: www.clinicaltrials.gov/ct2/show/NCT00168389 [Last accessed 24 September 2010]
68. Clinical Trials.gov. A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema. Clinical. Available from: www.clinicaltrials.gov/ct2/show/NCT00168337 [Last accessed 29 September 2010]
69. Clinical trials.gov. Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema. Available from: http://clinicaltrials.gov/ct2/show/NCT00464685 [Last accessed 27 September 2010]
70. Kuno N, Fujii S. Biodegradable Intraocular therapies for retinal disorders. Drugs Aging 2010;27(2):117-34
71. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. 15. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16
72. Aroca PR, Salvat M, Fernandez J, et al. Risk factors for diffuse and focal macular edem. J Diabetes Complications 2004;18:211-15
73. Klein R, Knudtson MD, Lee KE, et al. The wisconsin epidemiologic eye study of diabetic retinopathy. 23. The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503 A landmark study.
74. Matthews DR, Stratton IM, Aldington SJ, et al. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol 2004;122:1631-40
75. West KM, Erdreich LJ, Stober A. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 1980;29:501-8
76. Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996;103:1438-42 A landmark study.
77. Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 2007;76:S31-9
78. Penha FM, Rodrigues EB, Maia M, et al. Retinal and ocular toxicity in ocular application of drugs and chemicals-Part II: retinal toxicity of current and new drugs. Ophthalmic Res 2010;44(4):205-24
79. Andrade RE, Muccioli C, Farah ME, et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-4
80. Francis BA, Chang EL, Haik BG. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology 1996;103:1884-8
81. Goldfien A. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, editor, Basic and clinical pharmacology. 6th edition. Prentice Hall International, London; 1995. p. 592-607
82. Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007;52(5):503-22
83. Kwak HW, DAmico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259-66
84. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age related macular degeneration. Ophthalmology 2006;113:14-22
85. Chan CKM, Shaheeda M, Lee VYW, et al. Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthalmic Surg Lasers Imaging 2010;41:26-30
86. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
87. Ehmann D, Garcia R. Triple therapy for neovascular age-related macular degeneration (verteprofin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol 2010;45(1):36-40
88. Augustin AJ. Triple therapy for age-related macular degeneration. Retina 2009;29:S8-11